How to Build an Obesity Phenotype Step-by-Step, with Andres Acosta, MD, PhD
Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.
Daily Dose: Early Oseltamivir in Hospitalized Children with Influenza
Your daily dose of clinical news you may have missed.
Investigational Fentanyl Vaccine Could Block the Opioid from the Brain
A vaccine against fentanyl could stop the intense euphoria the drug creates and also block dangerous physiologic responses like respiratory depression, a new study suggests.
Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.
Dupilumab Pooled Phase 3 Trial Data Broadly Support FDA Approval for EoE
Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.
Andres Acosta, MD, Discusses the Challenge of Heterogeneity in Response to Obesity Treatment
Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.
Daily Dose: Remote Hypertension and Lipid Program
Large Analysis of Hospitalized Children with Influenza Supports Early Oseltamivir Treatment
Early oseltamivir use reduced the length of hospitalization and risk for hospital readmission in children hospitalized with influenza, according to new research.
Baxdrostat in Phase 2 Clinical Trial Proves Effective, Safe in Treatment-resistant Hypertension
Baxdrostat shows potential to represent the first new class of antihypertensive agents approved since 2017.
Fully Remote Intervention for Hypertension, Lipids Proves Feasible, Successful in Large, Diverse Health Care Network
The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.
Daily Dose: Social Vulnerabilities Linked to Cardiometabolic Risk in Pregnant Women
AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
5 Cities Benefitting Most & Least from New Medical Debt Credit Reporting Changes
Equifax, Experian, and TransUnion announced 3 major changes to medical debt reporting, expected to remove ~70% of medical collection debt tradelines from consumer credit reports.
Vaccine Confidence Significantly Eroded During Pandemic, Across Demographics
Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.
Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Obesity Research Roundup for Primary Care: 5 Studies At-a-Glance from ObesityWeek® 2022
Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.
Conversations Around Pediatric Obesity: Communicating with Compassion
Weight management in children and adolescents with obesity requires unique sensitivity to the physical and emotional needs of these vulnerable pediatric patients.
Daily Dose: Racial Disparities among Women Seeking Fertility Care
Social Vulnerabilities Linked to Cardiometabolic Risk in Pregnant Women in US, New Study Finds
AHA 2022: Study authors say more research is needed to investigate the impact of targeting social determinants of health to improve cardiometabolic risk and mortality in pregnant women.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
